THIS MONTH’S ISSUE

Read, save, and print articles from the current issue

ARTICLES

Chronological index
2013–2016

PRODUCT GUIDES

Compare all instruments
and software systems

DEPARTMENTS

Chronological index
2013–2016

MARKETPLACE

New pathology lab products and industry news

Home » Top news

Horizon license for gene editing platform

July 13, 2017Horizon Discovery Group has completed licensing agreements with all joint patent holders to provide exclusive worldwide rights to a novel transposon-based gene editing technology platform.

The license broadens Horizon’s gene editing capabilities, with immediate applications in biomanufacturing, diagnostics, and cell therapy. For diagnostics, Horizon can use the technology to efficiently develop reference standards for assays designed to measure the copy number of a gene.

The technology is based on a type of transposon (Helitron), which uses a “copy and paste” mechanism to allow multiple copies of a DNA sequence to be incorporated into a genome, either immediately or by reactivating the transposon machinery to increase the copy number at a later time. This is in contrast to current transposon technologies, which transfer DNA by a “cut and paste” mechanism, where a sequence is removed from one part of a genome and randomly inserted elsewhere.

More top news

Print Friendly
Tags:

X